

<b>Supplement 5</b>	<b>Effect estimates for all adverse events with subgroups</b>	
	a. Infection & respiratory system	p. 2-4
	b. Gastro-intestinal tract	p. 5-7
	c. CNS & behaviour effects	p. 8-9
	d. Dermatologic conditions	p. 10
	e. Endocrine/ metabolic & musculoskeletal systems	p. 11
	f. Cardiovascular system	p. 12
	g. General adverse events/ other symptoms	p. 13
	h. Immune system & oncology	p. 14

The tables below report results of meta-analyses for adverse events, organized by organ systems.

Effect estimates were calculated for studies with more than one treatment arm, using risk difference (RD) for all comparative studies and, using Peto odds ratio (pOR) for studies that reported at least one event in at least one treatment arm. Shaded rows indicate all studies contributing to an outcome, for the specified comparison, without subgroup analysis. When data was available, subgroup analyses (non-shaded rows) using study-level data were conducted for dose (single versus multi-dose) and for respiratory condition (e.g., bronchiolitis).

**Supplement 5a. Infection & respiratory system**

<b>Adverse event</b>	<b>Comparison 1 vs. Comparison 2</b>	<b>Subgroup</b>	<b>No. of studies</b>	<b>Comparison 1 – no. of patients with events/total no. of patients</b>	<b>Comparison 2 – no. of patients with events/total no. of patients</b>	<b>RD (95% CI)</b>	<b>I<sup>2</sup> (%)</b>	<b>Peto OR (95% CI)</b>	<b>I<sup>2</sup> (%)</b>
Severe infections, overall	Systemic vs. placebo		4	0/552	2/554	0.00 (-0.01, 0.00)	0	0.15 (0.01, 2.45)	0
Severe infections, by dose	Systemic vs. placebo	Single dose	1	0/359	1/361	0.00 (-0.01, 0.00)	NA	0.14 (0.00, 6.86)	NA
	Systemic vs. placebo	Multi-dose	3	0/193	1/193	0.00 (-0.01, 0.01)	0	0.17 (0.00, 8.79)	NA
Severe infections, by condition	Systemic vs. placebo	Bronchiolitis	2	0/179	0/175	0.00 (-0.01, 0.01)	0	NA	NA
	Systemic vs. placebo	Croup	2	0/373	2/379	0.00 (-0.01, 0.00)	0	0.15 (0.01, 2.45)	0
Severe infections, overall	Inhaled vs. placebo		1	2/62	4/67	-0.03 (-0.10, 0.04)	NA	0.54 (0.11, 2.77)	NA
Systemic infections, overall	Systemic vs. placebo		4	5/1095	4/1083	0.00 (0.00, 0.00)	0	1.26 (0.34, 4.68)	NA
Systemic infections, by dose	Systemic vs. placebo	Single dose	2	5/664	4/656	0.00 (-0.01, 0.01)	0	1.26 (0.34, 4.68)	NA
	Systemic vs. placebo	Multi-dose	2	0/431	0/427	0.00 (-0.01, 0.01)	0	NA	NA
Systemic infections, by condition	Systemic vs. placebo	Bronchiolitis	2	0/705	0/695	0.00 (0.00, 0.00)	0	NA	NA
	Systemic vs. placebo	Croup	1	5/359	4/361	0.00 (-0.01, 0.02)	NA	1.26 (0.34, 4.68)	NA
	Systemic vs. placebo	Wheeze	1	0/31	0/27	0.00 (-0.07, 0.07)	NA	NA	NA

Systemic infections, overall	Inhaled vs. placebo	Multi-dose, wheeze	2	18/91	20/94	0.00 (-0.06, 0.06)	0	0.96 (0.45, 2.05)	NA
Lung/trachea, overall	Systemic vs. placebo		7	18/955	28/928	-0.01 ( -0.02, 0.01)	37	0.61 (0.34, 1.12)	0
Lung/trachea, by dose	Systemic vs. placebo	Single dose	5	6/793	9/761	0.00 (-0.01, 0.00)	0	0.57 (0.20, 1.62)	0
	Systemic vs. placebo	Multi-dose	2	12/162	19/167	-0.09 (-0.29, 0.10)	69	0.63 (0.30, 1.33)	57
Lung/trachea, by condition	Systemic vs. placebo	Bronchiolitis	3	12/542	19/529	-0.02 (-0.05, 0.02)	61	0.61 (0.29, 1.28)	30
	Systemic vs. placebo	Croup	4	6/413	9/399	-0.02 (-0.12, 0.07)	40	0.61 (0.21, 1.76)	6
Lung/trachea, overall	Inhaled vs. placebo	Multi-dose, wheeze	1	13/62	10/67	0.06 (-0.07, 0.19)	NA	1.51 (0.61, 3.70)	NA
URT, overall	Systemic vs. placebo		6	9/671	7/656	0.00 (-0.01, 0.01)	0	1.21 (0.44, 3.33)	0
URT, by dose	Systemic vs. placebo	Single dose	4	1/492	1/480	0.00 (-0.01, 0.01)	0	0.46 (0.02, 10.18)	0
	Systemic vs. placebo	Multi-dose	2	8/179	6/176	0.01 (-0.03, 0.05)	0	1.36 (0.47, 3.96)	NA
URT, by condition	Systemic vs. placebo	Bronchiolitis	1	8/148	6/149	0.01 (-0.03, 0.06)	NA	1.36 (0.47, 3.96)	NA
URT, by condition	Systemic vs. placebo	Croup	4	1/492	1/480	0.00 (-0.01, 0.01)	0	0.46 (0.02, 10.18)	0
	Systemic vs. placebo	Wheeze	1	0/31	0/27	0.00 (-0.07, 0.07)	NA	NA	NA
URT, overall	Inhaled vs. placebo		6	24/495	24/499	0.00 (-0.02, 0.02)	0	1.03 (0.57, 1.85)	21
URT, by dose	Inhaled vs. placebo	Single dose	3	2/140	0/144	0.00 (-0.02, 0.03)	14	7.40 (0.45, 121.47)	NA
	Inhaled vs. placebo	Multi-dose	3	22/355	24/355	-0.01 (-0.04, 0.03)	0	0.93 (0.51, 1.71)	0

URT, by condition	Inhaled vs. placebo	Croup	3	2/140	0/144	0.00 (-0.02, 0.03)	14	7.40 (0.45, 121.47)	NA
	Inhaled vs. placebo	Wheeze	3	22/355	24/355	-0.01 (-0.04, 0.03)	0	0.93 (0.51, 1.71)	0
Voice complaints, overall	Systemic vs. placebo		1	0/31	0/27	0.00 (-0.07, 0.07)	NA	NA	NA
Voice complaints, overall	Inhaled vs. placebo	All multi-dose	4	38/343	43/337	-0.01 (-0.10, 0.07)	64	0.85 (0.53, 1.36)	73
Voice complaints, by condition	Inhaled vs. placebo	Asthma	2	4/50	9/49	-0.08 (-0.46, 0.31)	90	0.39 (0.12, 1.26)	81
	Inhaled vs. placebo	Wheeze	2	34/293	34/288	0.00 (-0.04, 0.04)	0	0.99 (0.59, 1.64)	NA

RD: risk difference; CI: confidence interval; NA not applicable/estimable; no.: number; Peto OR: Peto odds ratio; URT=upper respiratory tract; vs.: versus

**Supplement 5b. Gastro-intestinal tract**

<b>Adverse event</b>	<b>Comparison 1 vs. Comparison 2</b>	<b>Subgroup</b>	<b>No. of studies</b>	<b>Comparison 1 – no. of patients with events/total no. of patients</b>	<b>Comparison 2 – no. of patients with events/total no. of patients</b>	<b>RD (95% CI)</b>	<b>I<sup>2</sup> (%)</b>	<b>Peto OR (95% CI)</b>	<b>I<sup>2</sup> (%)</b>
Bleeding, overall	Systemic vs. placebo		7	31/1287	31/1262	0.00 (0.00, 0.00)	0	1.00 (0.60, 1.67)	0
Bleeding, by dose	Systemic vs. placebo	Single dose	4	2/800	1/790	0.00 (0.00, 0.00)	0	1.87 (0.19, 18.27)	NA
	Systemic vs. placebo	Multi-dose	3	29/487	30/472	0.00 (-0.02, 0.02)	0	0.96 (0.57, 1.64)	0
Bleeding, by condition	Systemic vs. placebo	Bronchiolitis	5	31/881	31/852	0.00 (-0.01, 0.01)	0	1.00 (0.60, 1.67)	0
	Systemic vs. placebo	Croup	2	0/406	0/410	0.00 (-0.01, 0.01)	0	NA	NA
Bleeding, overall	Inhaled vs. placebo	Single dose, croup	1	0/48	0/49	0.00 (-0.04, 0.04)	NA	NA	NA
Vomiting, overall	Systemic vs. placebo		7	38/1603	34/1573	0.00 (0.00, 0.01)	0	1.10 (0.69, 1.76)	17
Vomiting, by dose	Systemic vs. placebo	Single dose	4	21/747	23/712	0.00 (-0.02, 0.01)	0	0.87 (0.47, 1.59)	24
	Systemic vs. placebo	Multi-dose	3	17/856	11/861	0.00 (-0.01, 0.02)	37	1.58 (0.75, 3.36)	0
Vomiting, by condition	Systemic vs. placebo	Asthma	1	1/37	5/33	-0.11 (-0.27, 0.06)	33	0.19 (0.03, 1.02)	0
	Systemic vs. placebo	Bronchiolitis	3	24/751	21/718	0.00 (-0.02, 0.02)	0	1.12 (0.62, 2.04)	0
	Systemic vs. placebo	Croup	1	3/359	4/361	0.00 (-0.02, 0.01)	NA	0.75 (0.17, 3.34)	NA

	Systemic vs. placebo	Wheeze	2	10/456	4/461	0.02 (-0.06, 0.11)	87	2.55 (0.87, 7.46)	0
Vomiting, overall	Inhaled vs. placebo		5	28/421	28/420	0.00 (-0.03, 0.04)	0	1.00 (0.58, 1.72)	0
Vomiting, by dose	Inhaled vs. placebo	Single dose	1	2/25	1/25	0.04 (-0.09, 0.17)	NA	2.00 (0.20, 20.20)	NA
	Inhaled vs. placebo	Multi-dose	4	26/396	27/395	0.00 (-0.03, 0.03)	0	0.96 (0.55, 1.67)	0
Vomiting, by condition	Inhaled vs. placebo	Asthma	1	1/28	0/27	0.04 (-0.06, 0.13)	NA	7.13 (0.14, 359.55)	NA
	Inhaled vs. placebo	Croup	2	4/67	4/65	0.00 (-0.08, 0.08)	0	0.97 (0.23, 4.00)	0
	Inhaled vs. placebo	Wheeze	2	23/326	24/328	0.00 (-0.04, 0.04)	0	0.96 (0.53, 1.74)	0
Vomiting, overall	Dexamethasone vs. other steroid		6	12/663	51/710	-0.06 (-0.09, -0.02)	58	0.29 (0.17, 0.48)	0
Vomiting, by dose	Dexamethasone vs. other steroid	Single dose	5	6/376	39/420	-0.07 (-0.11, -0.02)	47	0.23 (0.12, 0.42)	0
	Dexamethasone vs. other steroid	Multi-dose	1	6/287	12/290	-0.02 (-0.05, -0.01)	NA	0.51 (0.20, 1.30)	NA
Vomiting, by condition	Dexamethasone vs. other steroid	Asthma	3	6/466	28/466	-0.05 (-0.11, 0.00)	77	0.26 (0.13, 0.52)	52
	Dexamethasone vs. other steroid	Croup	2	5/111	8/75	-0.04 (-0.16, 0.08)	64	0.46 (0.14, 1.45)	0
	Dexamethasone vs. other steroid	Other conditions	1	1/86	15/169	-0.08 (-0.13, -0.02)	3	0.25 (0.09, 0.72)	0
Abdominal pain, overall	Systemic vs. placebo	Single dose, croup	1	1/359	1/361	0.00 (-0.01, 0.01)	NA	1.01 (0.06, 16.11)	NA
Abdominal pain, overall	Dexamethasone vs. other steroid		3	29/188	48/264	-0.01 (-0.07, 0.05)	0	0.96 (0.57, 1.61)	0

Abdominal pain, by condition	Dexamethasone vs. other steroid	Asthma	1	2/56	3/54	-0.02 (-0.10, 0.06)	NA	0.64 (0.11, 3.79)	NA
		Croup	1	9/46	7/41	0.02 (-0.14, 0.19)	NA	1.18 (0.40, 3.47)	NA
		Other conditions	1	18/86	38/169	-0.01 (-0.12, 0.10)	0	0.94 (0.50, 1.77)	0
Diarrhea, overall	Systemic vs. placebo		3	10/254	9/230	0.01 (-0.03, 0.04)	0	1.09 (0.43, 2.73)	0
Diarrhea, by dose	Systemic vs. placebo	Single dose	1	3/89	3/85	0.00 (-0.06, 0.05)	NA	0.95 (0.19, 4.84)	NA
	Systemic vs. placebo	Multi-dose	2	7/165	6/145	0.01 (-0.03, 0.05)	0	1.16 (0.38, 3.54)	0
Diarrhea, by condition	Systemic vs. placebo	Bronchiolitis	1	3/89	3/85	0.00 (-0.06, 0.05)	NA	0.95 (0.19, 4.84)	NA
	Systemic vs. placebo	Wheeze	2	7/165	6/145	0.01 (-0.03, 0.05)	0	1.16 (0.38, 3.54)	0
Diarrhea, overall	Inhaled vs. placebo	Multi-dose, wheeze	2	41/326	46/328	-0.01 (-0.09, 0.08)	37	0.89 (0.57, 1.40)	44

RD: risk difference; CI: confidence interval; NA: not applicable/estimable; no.: number; Peto OR: Peto odds ratio; vs.: versus

**Supplement 5c. CNS & behavior effects**

<b>Adverse event</b>	<b>Comparison 1 vs. Comparison 2</b>	<b>Subgroup</b>	<b>No. of studies</b>	<b>Comparison 1 – no. of patients with events/total no. of patients</b>	<b>Comparison 2 – no. of patients with events/total no. of patients</b>	<b>RD (95% CI)</b>	<b>I<sup>2</sup> (%)</b>	<b>Peto OR (95% CI)</b>	<b>I<sup>2</sup> (%)</b>
Tremor/jitteriness, overall	Systemic vs. placebo		5	22/559	14/508	0.01 (-0.01, 0.03)	0	1.44 (0.71, 2.92)	0
Tremor/jitteriness, by dose	Systemic vs. placebo	Single dose	2	9/83	7/56	0.00 (-0.08, 0.08)	0	1.15 (0.36, 3.66)	0
	Systemic vs. placebo	Multi-dose	3	13/476	7/452	0.01 (-0.01, 0.03)	0	1.65 (0.67, 4.02)	0
Tremor/jitteriness, by condition	Systemic vs. placebo	Asthma	1	9/37	7/33	0.01 (-0.16, 0.18)	0	1.15 (0.36, 3.66)	0
		Bronchiolitis	3	10/470	6/447	0.01 (-0.01, 0.03)	0	1.66 (0.62, 4.46)	0
		Wheeze	1	3/52	1/28	0.02 (-0.07, 0.12)	NA	1.58 (0.19, 12.83)	NA
Tremor/jitteriness, overall	Dexamethasone vs. other steroid	Single dose, croup	1	1/46	0/41	0.02 (-0.04, 0.08)	NA	6.63 (0.13, 336.21)	NA
Behaviour change, overall	Systemic vs. placebo		4	7/588	3/571	0.00 (-0.01, 0.02)	19	1.95 (0.55, 6.92)	0
Behaviour change, by dose	Systemic vs. placebo	Single dose	2	1/423	1/426	0.00 (-0.01, 0.01)	0	1.01 (0.06, 16.11)	NA
	Systemic vs. placebo	Multi-dose	2	6/165	2/145	0.02 (-0.02, 0.06)	11	2.32 (0.56, 9.64)	0
Behaviour change, by condition	Systemic vs. placebo	Croup	2	1/423	1/426	0.00 (-0.01, 0.01)	0	1.01 (0.06, 16.11)	NA
	Systemic vs. placebo	Wheeze	2	6/165	2/145	0.02 (-0.02, 0.06)	11	2.32 (0.56, 9.64)	0
Behaviour change, overall	Inhaled vs. placebo		3	6/134	7/135	-0.01 (-0.04, 0.03)	0	0.81 (0.26, 2.54)	0



Behaviour change, by dose	Inhaled vs. placebo	Single dose	1	0/64	1/68	-0.01 (-0.06, 0.03)	NA	0.14 (0.00, 7.25)	NA
	Inhaled vs. placebo	Multi-dose	2	6/70	6/67	0.02 (-0.06, 0.10)	0	0.95 (0.28, 3.15)	11
Behaviour change, by condition	Inhaled vs. placebo	Asthma	1	1/28	0/27	0.04 (-0.06, 0.13)	NA	7.13 (0.14, 359.55)	NA
	Inhaled vs. placebo	Croup	2	5/106	7/108	-0.02 (-0.05, 0.02)	0	0.66 (0.20, 2.18)	0
Behaviour change, overall	Dexamethasone vs. other steroid	All single dose	2	35/60	38/57	-0.08 (-0.25, 0.09)	0	0.73 (0.34, 1.56)	0
Behaviour change, by condition	Dexamethasone vs. other steroid	Asthma	1	10/14	14/16	-0.16 (-0.45, 0.13)	NA	0.38 (0.06, 2.21)	NA
	Dexamethasone vs. other steroid	Croup	1	25/46	24/41	-0.04 (-0.25, 0.17)	NA	0.85 (0.36, 1.97)	NA
Headache, overall	Systemic vs. placebo	Single dose, asthma	1	0/37	1/33	-0.02 (-0.10, 0.07)	0	0.11 (0.00, 5.68)	NA
Headache, overall	Dexamethasone vs. other steroid	All single dose	2	7/102	4/95	0.02 (-0.08, 0.11)	51	1.63 (0.46, 5.74)	NA
Headache, by condition	Dexamethasone vs. other steroid	Asthma	1	0/56	0/54	0.00 (-0.03, 0.03)	NA	NA	NA
		Croup	1	7/46	4/41	0.05 (-0.08, 0.19)	NA	1.63 (0.46, 5.74)	NA

RD: risk difference; CI: confidence interval; NA: not applicable/estimable; no.: number; Peto OR: Peto odds ratio; vs.: versus

**Supplement 5d. Dermatologic conditions**

<b>Adverse event</b>	<b>Comparison 1 vs. Comparison 2</b>	<b>Subgroup</b>	<b>No. of studies</b>	<b>Comparison 1 – no. of patients with events/total no. of patients</b>	<b>Comparison 2 – no. of patients with events/total no. of patients</b>	<b>RD (95% CI)</b>	<b>I<sup>2</sup> (%)</b>	<b>Peto OR (95% CI)</b>	<b>I<sup>2</sup> (%)</b>
Burn, overall	Inhaled vs. placebo	Single dose, croup	1	0/27	1/27	-0.04 (-0.13, 0.06)	NA	0.14 (0.00, 6.82)	NA
Integument, overall	Systemic vs. placebo		3	4/536	0/543	0.01 (0.00, 0.01)	0	7.59 (1.07, 54.01)	0
Integument, by dose	Systemic vs. placebo	Single dose	2	2/423	0/426	0.01 (0.00, 0.01)	0	7.45 (0.47, 119.36)	NA
	Systemic vs. placebo	Multi-dose	1	2/133	0/117	0.02 (-0.01, 0.05)	NA	7.72 (0.48, 124.29)	NA
Integument, by condition	Systemic vs. placebo	Croup	2	2/423	0/426	0.01 (0.00, 0.01)	0	7.45 (0.47, 119.36)	NA
	Systemic vs. placebo	Wheeze	1	2/113	0/117	0.02 (-0.01, 0.05)	NA	7.72 (0.48, 124.29)	NA
Integument, overall	Inhaled vs. placebo		4	24/432	27/436	-0.01 (-0.04, 0.02)	11	0.88 (0.50, 1.56)	37
Integument, by dose	Inhaled vs. placebo	Single dose	1	0/64	1/68	-0.01 (-0.06, 0.03)	NA	0.14 (0.00, 7.25)	NA
	Inhaled vs. placebo	Multi-dose	3	24/368	26/368	-0.01 (-0.05, 0.04)	38	0.92 (0.52, 1.63)	49
Integument, by condition	Inhaled vs. placebo	Croup	2	0/106	3/108	-0.02 (-0.06, 0.01)	0	0.13 (0.01, 1.27)	0
	Inhaled vs. placebo	Wheeze	2	24/326	24/328	0.01 (-0.05, 0.07)	46	1.00 (0.56, 1.80)	47
Phlebitis, overall	Dexamethasone vs. other steroid	Single dose, asthma	1	0/15	0/17	0.00 (-0.11, 0.11)	NA	NA	NA

RD: risk difference; CI: confidence interval; NA: not applicable/estimable; no.: number; Peto OR: Peto odds ratio; vs.: versus

**Supplement 5e. Endocrine/metabolic & musculoskeletal systems**

<b>Adverse event</b>	<b>Comparison 1 vs. Comparison 2</b>	<b>Subgroup</b>	<b>No. of studies</b>	<b>Comparison 1 – no. of patients with events/total no. of patients</b>	<b>Comparison 2 – no. of patients with events/total no. of patients</b>	<b>RD (95% CI)</b>	<b>I<sup>2</sup> (%)</b>	<b>Peto OR (95% CI)</b>	<b>I<sup>2</sup> (%)</b>
Fluid & electrolyte abnormalities, overall	Systemic vs. placebo		4	5/832	1/818	0.00 (0.00, 0.01)	0	3.08 (0.60, 15.94)	0
Fluid & electrolyte abnormalities, by dose	Systemic vs. placebo	Single dose	1	1/359	0/361	0.00 (0.00, 0.01)	NA	7.43 (0.15, 374.47)	NA
	Systemic vs. placebo	Multi-dose	3	4/473	1/457	0.00 (-0.01, 0.01)	0	2.56 (0.42, 15.61)	0
Fluid & electrolyte abnormalities, by condition	Systemic vs. placebo	Bronchiolitis	2	4/448	1/432	0.00 (-0.01, 0.01)	0	2.56 (0.42, 15.61)	0
	Systemic vs. placebo	Croup	2	1/384	0/386	0.00 (0.00, 0.01)	0	7.43 (0.15, 374.47)	NA
Fluid & electrolyte abnormalities, overall	Dexamethasone vs. other steroid	Multi-dose, bronchiolitis	1	1/33	2/15	-0.10 (-0.28, 0.08)	NA	0.18 (0.01, 2.17)	NA
Adrenal suppression, overall	Inhaled vs. placebo	Multi-dose, asthma	1	5/6	4/10	0.43 (0.01, 0.86)	NA	5.21 (0.72, 37.57)	NA

RD: risk difference; CI: confidence interval; NA: not applicable/estimable; no.: number; Peto OR: Peto odds ratio; vs.: versus

<b>Adverse event</b>	<b>Comparison 1 vs. Comparison 2</b>	<b>Subgroup</b>	<b>No. of studies</b>	<b>Comparison 1 – total no. of patients</b>	<b>Comparison 2 – total no. of patients</b>	<b>Mean Difference (95% CI)</b>	<b>I<sup>2</sup> (%)</b>
Linear growth	Inhaled vs. placebo	Multi-dose, wheeze	2	154	109	0.10 (-0.47, 0.67)	9

CI: confidence interval; no.: number; vs.: versus

**Supplement 5f. Cardiovascular system**

<b>Adverse event</b>	<b>Comparison 1 vs. Comparison 2</b>	<b>Subgroup</b>	<b>No. of studies</b>	<b>Comparison 1 – no. of patients with events/total no. of patients</b>	<b>Comparison 2 – no. of patients with events/total no. of patients</b>	<b>RD (95% CI)</b>	<b>I<sup>2</sup> (%)</b>	<b>Peto OR (95% CI)</b>	<b>I<sup>2</sup> (%)</b>
Arrhythmia, overall	Systemic vs. placebo	Multi-dose, wheeze	1	0/31	0/27	0.00 (-0.07, 0.07)	NA	NA	NA
Arrhythmia, overall	Inhaled vs. placebo	Multi-dose, wheeze	1	0/29	0/27	0.00 (-0.07, 0.07)	NA	NA	NA
Arrhythmia, overall	Dexamethasone vs. other steroid	Multi-dose, asthma	1	0/56	0/54	0.00 (-0.03, 0.03)	NA	NA	NA
Hypertension, overall	Systemic vs. placebo	All bronchiolitis	3	1/727	1/714	0.00 (-0.01, 0.01)	0	1.00 (0.06, 15.99)	50
Hypertension, by dose	Systemic vs. placebo	Single dose	1	0/305	0/295	0.00 (-0.01, 0.01)	NA	NA	NA
	Systemic vs. placebo	Multi-dose	2	1/422	1/419	0.00 (-0.01, 0.01)	0	1.00 (0.06, 15.99)	50
Hypertension, overall	Dexamethasone vs. other steroid	Single dose, asthma	1	0/15	0/17	0.00 (-0.11, 0.11)	NA	NA	NA
Congestive heart failure, overall	Systemic vs. placebo	Multi-dose, croup	1	0/25	0/25	0.00 (-0.07, 0.07)	NA	NA	NA

RD: risk difference; CI: confidence interval; NA: not applicable/estimable; no.: number; Peto OR: Peto odds ratio; vs.: versus

**Supplement 5g. General adverse events/ other symptoms**

<b>Adverse event</b>	<b>Comparison 1 vs. Comparison 2</b>	<b>Subgroup</b>	<b>No. of studies</b>	<b>Comparison 1 – no. of patients with events/total no. of patients</b>	<b>Comparison 2 – no. of patients with events/total no. of patients</b>	<b>RD (95% CI)</b>	<b>I<sup>2</sup> (%)</b>	<b>Peto OR (95% CI)</b>	<b>I<sup>2</sup> (%)</b>
General complaints <sup>1</sup> , overall	Systemic vs. placebo	All bronchiolitis	2	38/446	38/423	0.00 (-0.04, 0.04)	0	1.00 (0.62, 1.60)	0
General complaints, by dose	Systemic vs. placebo	Single dose	1	0/46	0/23	0.00 (-0.09, 0.09)	0	NA	NA
	Systemic vs. placebo	Multi-dose	1	38/400	38/400	0.00 (-0.04, 0.04)	0	1.00 (0.62, 1.60)	0
General complaints <sup>2</sup> , overall	Dexamethasone vs. other steroid		2	3/102	3/95	-0.01 (-0.06, 0.03)	0	0.90 (0.18, 4.61)	11
General complaints, by condition	Dexamethasone vs. other steroid	Asthma	1	0/56	1/54	-0.02 (-0.07, 0.03)	NA	0.13 (0.00, 6.58)	NA
	Dexamethasone vs. other steroid	Croup	1	3/46	2/41	0.01 (-0.08, 0.11)	NA	1.29 (0.21, 7.81)	NA

<sup>1</sup>Two studies reported pallor

<sup>2</sup>One study reported excessive urination; one study reported dizziness

RD: risk difference; CI: confidence interval; NA: not applicable/estimable; no.: number; Peto OR: Peto odds ratio; vs.: versus

**Supplement 5h. Immune system & oncology**

<b>Adverse event</b>	<b>Comparison 1 vs. Comparison 2</b>	<b>Subgroup</b>	<b>No. of studies</b>	<b>Comparison 1 –no.# of patients with events/total no. of patients</b>	<b>Comparison 2 – no. of patients with events/total no. of patients</b>	<b>RD (95% CI)</b>	<b>I<sup>2</sup> (%)</b>	<b>Peto OR (95% CI)</b>	<b>I<sup>2</sup> (%)</b>
Immunosuppression, overall	Systemic vs. placebo		1	0/47	0/48	0.00 (-0.04, 0.04)	NA	NA	NA

RD: risk difference; CI: confidence interval; NA: not applicable/estimable; no.: number; Peto OR: Peto odds ratio; vs.: versus